Gerber, David E <br/><br/>
Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).  [electronic resource] 

 -  Clinical lung cancer  05 2017 
 - 333-339 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1938-0690 
<br/><br/><label>Standard No.: </label>10.1016/j.cllc.2016.10.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--mortality<br/>Chemoradiotherapy<br/>Cisplatin--therapeutic use<br/>Combined Modality Therapy<br/>Etoposide--therapeutic use<br/>Humans<br/>Immunotherapy--methods<br/>Lung Neoplasms--mortality<br/>Middle Aged<br/>Neoplasm Staging<br/>Nivolumab<br/>Placebo Effect<br/>Proportional Hazards Models<br/>Research Design<br/>Survival Analysis<br/>Young Adult